Corrigendum to "Evaluation of the distribution and excretion of [<sup>14</sup>C]-inclisiran following single subcutaneous administration in cynomolgus monkeys" [Toxicology and Applied Pharmacology 443 (2022) 115978].

Lehoux, Dario; Far, Adel Rafai; Kallend, David; Wijngaard, Peter L J; Zerler, Brad

Corrigendum to "Evaluation of the distribution and excretion of [¹⁴C]-inclisiran following single subcutaneous administration in cynomolgus monkeys" [Toxicology and Applied Pharmacology 443 (2022) 115978].

Lehoux, Dario; Far, Adel Rafai; Kallend, David; Wijngaard, Peter L J; Zerler, Brad.

Afiliação

Lehoux D; Targanta Therapeutics Inc., a wholly owned subsidiary of The Medicines Company, Saint Laurent, Quebec H4S 2A1, Canada.
Far AR; Targanta Therapeutics Inc., a wholly owned subsidiary of The Medicines Company, Saint Laurent, Quebec H4S 2A1, Canada. Electronic address: adel.rafai_far@novartis.com.
Kallend D; The Medicines Company (Schweiz) GmbH, Zurich 8001, Switzerland.
Wijngaard PLJ; The Medicines Company Inc., Parsippany, NJ 07054, USA.
Zerler B; The Medicines Company Inc., Parsippany, NJ 07054, USA.

Toxicol Appl Pharmacol ; 451: 116144, 2022 Sep 15.

Article em En | MEDLINE | ID: mdl-35780943

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Idioma: En Ano de publicação: 2022 Tipo de documento: Article

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Idioma: En Ano de publicação: 2022 Tipo de documento: Article